Presented at Uro conference this week:
urotoday.com/conference-hig...
Taking a look at the low volume / lower risk graphs is very hopeful to anyone in these categories.
Does anyone have a take on the curve flattening? Fewer numbers to be sure….
Subgroup Analysis from Arasens - daro... - Advanced Prostate...
Subgroup Analysis from Arasens - darolutamide / triplet therapy
Written by
Heykm01
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
ARASENS Darolutamide vs Placebo
Resistant Prostate Cancer Free survival probability (%) for two groups: (A) Darolutamide +...
ARASENS: Darolutamide + ADT + Docetaxel may become new SOC for mHSPC - from ASCO GU Symposium 2022
from 3 ARASENS trial results when compared to placebo + ADT + Docetaxel. A 32% reduction in the...
Triplet Therapy
sounds dumb, what I mean is that the spreading prostate cancer cannot be cured or removed. So does...
Age and timing for Triplet therapy?
again in 2023 for a pelvic node. In December the PSA rose to 3.78 and a PSMA-PET scan showed...
Another victory for \"triplet\"therapy for newly diagnosed metastatic men.
results of the ARASENS trial were presented at the 2022 ASCO Genitourinary Conference. All 1,306...
Triplet Therapy Failed. Now what?
PSA rising during triplet therapy. What to ask the oncologist?
Triplet Systemic Therapy for low volume mCSPC
ADT + darolutamide + docetaxel (ARASENS trial) has anyone tried it?
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
